The DOI matches its Crossref record; 257 of the 257 references it cites were found in a registry or an index.
Non-small-cell lung cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064 · cited 1×
“…mortality (relative reduction 20% (95% confidence interval (CI) 6.8–26.7; P = 0.004) for NLST and cumulative rate ratio at 10 years 0.76 (95% CI 0.61–0.94; P = 0.01) for NELSON), but only NLST showed a decrease in all-cause mortality (6.7% reduction (95% CI 1.2–13.6; P = 0.02)) 104,105 .”
InfluentialPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationHallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 1×
“Four phase III RCTs showed a significant survival benefit with ICBs compared with the standard second-line chemo-therapeutic agent docetaxel 214–217 .”
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
The functional assessment of cancer therapy scale: development and validation of the general measure
Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., & Brannon, J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.570 · Cited by 6,020
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732 · cited 2×
“16,61,62).”
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Self-citationNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · cited 1×
“One such important mechanism is tumour cell adoption of inhibitory immune checkpoints, whereby receptor–ligand interactions between tumour cells and immune cells (and between different immune cell types) effectively switch off an otherwise available antitumour immune response 79,80 .”
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911793 · Cited by 3,624
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · cited 2×
“Tobacco smoking remains the most important risk factor for lung cancer, with a relative risk of lung cancer 10–30 times higher (depending on daily smoked amount and pack-years) compared with never-smokers 17 .”
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer
Ginsberg, R. J., & Rubinstein, L. V. (1995) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00537-u · Cited by 3,006
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Non-small Cell Lung Cancer Collaborative Group (1995) · BMJ · doi:10.1136/bmj.311.7010.899 · Cited by 2,850
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825
Self-citationOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Self-citationSomatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 2×
“16,61,62).”
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642 · cited 1×
“The recommendation regarding the use of post-operative (adjuvant) chemotherapy is based on a large pooled analysis of five RCTs, and this approach is recommended for resected NSCLC with tumour size ≥4 cm or lymph node involvement, provided there are no medical contraindications 153 .”
Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Self-citationBradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849 · cited 1×
“In phase I/II trials, the KRAS inhibitors sotorasib and adagra-sib reported promising response and PFS data 205,206 .”
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027071 · Cited by 1,798
Saji, H., Okada, M., Tsuboi, M., Nakajima, R., Suzuki, K., Aokage, K., Aoki, T., Okami, J., Yoshino, I., Ito, H., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02333-3 · Cited by 1,729
The Effect of Advances in Lung-Cancer Treatment on Population Mortality
Howlader, N., Forjaz, G., Mooradian, M. J., Meza, R., Kong, C. Y., Cronin, K. A., Mariotto, A. B., Lowy, D. R., & Feuer, E. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916623 · Cited by 1,712
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 1×
“65,66) or a baseline mutation in the TSG SMARCA4 can reduce the efficacy of ICBs 67 .”
Self-citationGlobal Epidemiology of Lung Cancer
Barta, J. A., Powell, C. A., & Wisnivesky, J. P. (2019) · Annals of Global Health · doi:10.5334/aogh.2419 · Cited by 1,575
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Self-citationFelip, E., Altorki, N., Zhou, C., Csőszi, T., Vynnychenko, I., Goloborodko, O., Luft, A., Akopov, A., Martinez-Marti, A., Kenmotsu, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02098-5 · Cited by 1,486
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01308 · Cited by 1,445
Self-citationMazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,354
Gomez, D. R., Tang, C., Zhang, J., Blumenschein, G. R., Hernandez, M., Lee, J. J., Ye, R., Palma, D. A., Louie, A. V., Camidge, D. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00201 · Cited by 1,283
Self-citationGainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Brierley, J. D., Gospodarowicz, M. K., & Wittekind, C. (2017) · TNM Online · doi:10.1002/9780471420194.tnmc26.pub3 · Cited by 1,231
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180 · cited 3×
“To date, in contrast to CheckMate 816, all other phase III RCTs evaluating neoadjuvant chemotherapy plus ICB also incorporated an adjuvant ICB component (that is, a perioperative strategy) 161,162,164,165 .”
InfluentialReck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151 · cited 1×
“Targeted therapies also improve QOL compared with chemotherapy in patients with metastatic NSCLC and a targetable oncogenic driver 251–253 .”
Self-citationGenomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K. L., Maher, C. A., Fulton, R., Fulton, L., Wallis, J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,146
Bendixen, M., Jørgensen, O. D., Kronborg, C., Andersen, C., & Licht, P. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00173-x · Cited by 1,118
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117 · cited 2×
“Once invasive, malignant tumours continue to evolve through further genomic alterations, driving subclonal development and, usually, more aggressive disease 40–42 (Fig.”
Lobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer
Altorki, N., Wang, X., Kozono, D., Watt, C., Landrenau, R., Wigle, D., Port, J., Jones, D. R., Conti, M., Ashrafi, A. S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212083 · Cited by 1,106
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazieres, J., Kim, D.-W., Mok, T., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,099
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061 · cited 1×
“In phase I/II trials, the KRAS inhibitors sotorasib and adagra-sib reported promising response and PFS data 205,206 .”
Byers, L. A., Diao, L., Wang, J., Saintigny, P., Girard, L., Peyton, M., Shen, L., Fan, Y., Giri, U., Tumula, P. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1558 · Cited by 1,059
Self-citationIyengar, P., Wardak, Z., Gerber, D. E., Tumati, V., Ahn, C., Hughes, R. S., Dowell, J. E., Cheedella, N., Nedzi, L., Westover, K. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3501 · Cited by 1,047
Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer
Li, B. T., Smit, E. F., Goto, Y., Nakagawa, K., Udagawa, H., Mazières, J., Nagasaka, M., Bazhenova, L., Saltos, A. N., Felip, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2112431 · Cited by 1,021
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Self-citationBarlesi, F., Mazieres, J., Merlio, J.-P., Debieuvre, D., Mosser, J., Lena, H., Ouafik, L., Besse, B., Rouquette, I., Westeel, V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00004-0 · Cited by 1,004
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Risk factors for lung cancer worldwide
Malhotra, J., Malvezzi, M., Negri, E., La Vecchia, C., & Boffetta, P. (2016) · European Respiratory Journal · doi:10.1183/13993003.00359-2016 · Cited by 980
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., Seth, S., Chow, C.-W., Cao, Y., Gumbs, C., et al. (2014) · Science · doi:10.1126/science.1256930 · Cited by 965
Self-citationBrunelli, A., Charloux, A., Bolliger, C. T., Rocco, G., Sculier, J.-P., Varela, G., Licker, M., Ferguson, M. K., Faivre-Finn, C., Huber, R. M., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00184308 · Cited by 955
Self-citationSkoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936
Self-citationBergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90535-5 · Cited by 885
Non–Small Cell Lung Cancer, Version 4.2024
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 855
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 853
Self-citationLung adenocarcinoma promotion by air pollutants
Hill, W., Lim, E. L., Weeden, C. E., Lee, C., Augustine, M., Chen, K., Kuan, F.-C., Marongiu, F., Evans, E. J., Moore, D. A., et al. (2023) · Nature · doi:10.1038/s41586-023-05874-3 · Cited by 808
Self-citationWeinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 779
Self-citationPerioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer
Heymach, J. V., Harpole, D., Mitsudomi, T., Taube, J. M., Galffy, G., Hochmair, M., Winder, T., Zukov, R., Garbaos, G., Gao, S., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304875 · Cited by 778
Self-citationO’Brien, M., Paz-Ares, L., Marreaud, S., Dafni, U., Oselin, K., Havel, L., Esteban, E., Isla, D., Martinez-Marti, A., Faehling, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00518-6 · Cited by 774
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
Planchard, D., Jänne, P. A., Cheng, Y., Yang, J. C.-H., Yanagitani, N., Kim, S.-W., Sugawara, S., Yu, Y., Fan, Y., Geater, S. L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306434 · Cited by 740
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W.-C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304594 · Cited by 672
Thomson, S., Buck, E., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663
Hellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Le Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
Hendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Self-citationde Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619 · cited 1×
“However, in the phase III KRYSTAL-12 and CODEBREAK-200 trials, which compared adagrasib 207 or sotorasib 208 (respectively) with docetaxel as second-line treatment, both inhibitors only modestly improved PFS, with no improvement in overall survival for sotorasib; overall survival has not yet been…”
NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
Travis, W. D., Brambilla, E., & Riely, G. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9270 · Cited by 599
Le Rhun, E., Guckenberger, M., Smits, M., Dummer, R., Bachelot, T., Sahm, F., Galldiks, N., de Azambuja, E., Berghoff, A. S., Metellus, P., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.016 · Cited by 592
Perioperative Nivolumab in Resectable Lung Cancer
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lu, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2311926 · Cited by 527
Pastorino, U., Silva, M., Sestini, S., Sabia, F., Boeri, M., Cantarutti, A., Sverzellati, N., Sozzi, G., Corrao, G., & Marchianò, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz117 · Cited by 523
Di Maio, M., Basch, E., Denis, F., Fallowfield, L. J., Ganz, P. A., Howell, D., Kowalski, C., Perrone, F., Stover, A. M., Sundaresan, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.007 · Cited by 509
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
Lee, J.-K., Lee, J., Kim, S., Kim, S., Youk, J., Park, S., An, Y., Keam, B., Kim, D.-W., Heo, D. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9096 · Cited by 505
Denis, F., Lethrosne, C., Pourel, N., Molinier, O., Pointreau, Y., Domont, J., Bourgeois, H., Senellart, H., Trémolières, P., Lizée, T., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx029 · Cited by 482
Vokes, E. E., Herndon, J. E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., & Green, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3569 · Cited by 478
Remon, J., Soria, J.-C., & Peters, S. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1994 · Cited by 470
Self-citationAdams, S. J., Stone, E., Baldwin, D. R., Vliegenthart, R., Lee, P., & Fintelmann, F. J. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01694-4 · Cited by 467
Johnson, M. L., Cho, B. C., Luft, A., Alatorre-Alexander, J., Geater, S. L., Laktionov, K., Kim, S.-W., Ursol, G., Hussein, M., Lim, F. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00975 · Cited by 463
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J.-S., Lee, S.-H., Ostapenko, Y., Danchaivijitr, P., Liu, B., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403614 · Cited by 458
Lung cancer mortality reduction by LDCT screening—Results from the randomized German LUSI trial
Becker, N., Motsch, E., Trotter, A., Heussel, C. P., Dienemann, H., Schnabel, P. A., Kauczor, H., Maldonado, S. G., Miller, A. B., Kaaks, R., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32486 · Cited by 449
Sozzi, G., Boeri, M., Rossi, M., Verri, C., Suatoni, P., Bravi, F., Roz, L., Conte, D., Grassi, M., Sverzellati, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4357 · Cited by 436
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Wu, Y.-L., Dziadziuszko, R., Ahn, J. S., Barlesi, F., Nishio, M., Lee, D. H., Lee, J.-S., Zhong, W., Horinouchi, H., Mao, W., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2310532 · Cited by 431
Mosele, M. F., Westphalen, C. B., Stenzinger, A., Barlesi, F., Bayle, A., Bièche, I., Bonastre, J., Castro, E., Dienstmann, R., Krämer, A., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.04.005 · Cited by 415
Self-citationDeterminants and clinical implications of chromosomal instability in cancer
Sansregret, L., Vanhaesebroeck, B., & Swanton, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.198 · Cited by 396
Ricciuti, B., Arbour, K. C., Lin, J. J., Vajdi, A., Vokes, N., Hong, L., Zhang, J., Tolstorukov, M. Y., Li, Y. Y., Spurr, L. F., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.10.013 · Cited by 394
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Hanna, N. H. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79219-4 · Cited by 386
Lu, S., Zhang, W., Wu, L., Wang, W., Zhang, P., Neotorch Investigators, Fang, W., Xing, W., Chen, Q., Yang, L., et al. (2024) · JAMA · doi:10.1001/jama.2023.24735 · Cited by 383
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
Zhou, C., Tang, K.-J., Cho, B. C., Liu, B., Paz-Ares, L., Cheng, S., Kitazono, S., Thiagarajan, M., Goldman, J. W., Sabari, J. K., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306441 · Cited by 381
Rami-Porta, R., Nishimura, K. K., Giroux, D. J., Detterbeck, F., Cardillo, G., Edwards, J. G., Fong, K. M., Giuliani, M., Huang, J., Kernstine, K. H., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.02.011 · Cited by 376
Solomon, B. J., Liu, G., Felip, E., Mok, T. S. K., Soo, R. A., Mazieres, J., Shaw, A. T., de Marinis, F., Goto, Y., Wu, Y.-L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00581 · Cited by 374
Infante, M., Cavuto, S., Lutman, F. R., Passera, E., Chiarenza, M., Chiesa, G., Brambilla, G., Angeli, E., Aranzulla, G., Chiti, A., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1475oc · Cited by 365
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0011-0 · Cited by 365
Self-citationDurvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Cheng, Y., Spigel, D. R., Cho, B. C., Laktionov, K. K., Fang, J., Chen, Y., Zenke, Y., Lee, K. H., Wang, Q., Navarro, A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404873 · Cited by 358
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/j.ypdi.2015.02.054 · Cited by 353
Brahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30690-3 · Cited by 348
Self-citationOsimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
Lu, S., Kato, T., Dong, X., Ahn, M.-J., Quang, L.-V., Soparattanapaisarn, N., Inoue, T., Wang, C.-L., Huang, M., Yang, J. C.-H., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2402614 · Cited by 346
Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling
Wille, M. M. W., Dirksen, A., Ashraf, H., Saghir, Z., Bach, K. S., Brodersen, J., Clementsen, P. F., Hansen, H., Larsen, K. R., Mortensen, J., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-1040oc · Cited by 341
Immune evasion before tumour invasion in early lung squamous carcinogenesis
Mascaux, C., Angelova, M., Vasaturo, A., Beane, J., Hijazi, K., Anthoine, G., Buttard, B., Rothe, F., Willard-Gallo, K., Haller, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1330-0 · Cited by 331
Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S.-W., Planchard, D., Ahn, M.-J., Smit, E. F., de Langen, A. J., Pérol, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01361 · Cited by 328
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial
Paci, E., Puliti, D., Lopes Pegna, A., Carrozzi, L., Picozzi, G., Falaschi, F., Pistelli, F., Aquilini, F., Ocello, C., Zappa, M., et al. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-209825 · Cited by 311
Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies
Passaro, A., Brahmer, J., Antonia, S., Mok, T., & Peters, S. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01845 · Cited by 303
A Translational View of the Molecular Pathogenesis of Lung Cancer
Sato, M., Shames, D. S., Gazdar, A. F., & Minna, J. D. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000263718.69320.4c · Cited by 297
Negrao, M. V., Skoulidis, F., Montesion, M., Schulze, K., Bara, I., Shen, V., Xu, H., Hu, S., Sui, D., Elamin, Y. Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002891 · Cited by 294
Self-citationMikhael, P. G., Wohlwend, J., Yala, A., Karstens, L., Xiang, J., Takigami, A. K., Bourgouin, P. P., Chan, P., Mrah, S., Amayri, W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01345 · Cited by 288
Lung cancer in patients who have never smoked — an emerging disease
LoPiccolo, J., Gusev, A., Christiani, D. C., & Jänne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 286
miR-Test: A Blood Test for Lung Cancer Early Detection
Montani, F., Marzi, M. J., Dezi, F., Dama, E., Carletti, R. M., Bonizzi, G., Bertolotti, R., Bellomi, M., Rampinelli, C., Maisonneuve, P., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv063 · Cited by 278
Self-citationLe Pechoux, C., Pourel, N., Barlesi, F., Lerouge, D., Antoni, D., Lamezec, B., Nestle, U., Boisselier, P., Dansin, E., Paumier, A., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00606-9 · Cited by 276
Self-citationChmielecki, J., Gray, J. E., Cheng, Y., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35961-y · Cited by 274
Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions
Banfill, K., Giuliani, M., Aznar, M., Franks, K., McWilliam, A., Schmitt, M., Sun, F., Vozenin, M. C., & Faivre Finn, C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.002 · Cited by 272
Self-citationWang, X.-S., Bai, Y.-F., Verma, V., Yu, R.-L., Tian, W., Ao, R., Deng, Y., Zhu, X.-Q., Liu, H., Pan, H.-X., et al. (2023) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djac015 · Cited by 272
Jabbour, S. K., Lee, K. H., Frost, N., Breder, V., Kowalski, D. M., Pollock, T., Levchenko, E., Reguart, N., Martinez-Marti, A., Houghton, B., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2301 · Cited by 270
Self-citationFelip, E., Altorki, N., Zhou, C., Vallières, E., Martínez-Martí, A., Rittmeyer, A., Chella, A., Reck, M., Goloborodko, O., Huang, M., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.001 · Cited by 263
Self-citationBoyer, M., Şendur, M. A. N., Rodríguez-Abreu, D., Park, K., Lee, D. H., Çiçin, I., Yumuk, P. F., Orlandi, F. J., Leal, T. A., Molinier, O., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03579 · Cited by 247
Self-citationGirard, N., Bar, J., Garrido, P., Garassino, M. C., McDonald, F., Mornex, F., Filippi, A. R., Smit, H. J. M., Peters, S., Field, J. K., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.10.003 · Cited by 247
Self-citationEuropean cancer mortality predictions for the year 2017, with focus on lung cancer
Malvezzi, M., Carioli, G., Bertuccio, P., Boffetta, P., Levi, F., La Vecchia, C., & Negri, E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx033 · Cited by 244
Crosbie, P. A., Balata, H., Evison, M., Atack, M., Bayliss-Brideaux, V., Colligan, D., Duerden, R., Eaglesfield, J., Edwards, T., Elton, P., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2017-211377 · Cited by 242
Genomic and evolutionary classification of lung cancer in never smokers
Zhang, T., Joubert, P., Ansari-Pour, N., Zhao, W., Hoang, P. H., Lokanga, R., Moye, A. L., Rosenbaum, J., Gonzalez-Perez, A., Martínez-Jiménez, F., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00920-0 · Cited by 238
Hui, Z., Men, Y., Hu, C., Kang, J., Sun, X., Bi, N., Zhou, Z., Liang, J., Lv, J., Feng, Q., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.1910 · Cited by 233
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC
Zhou, C., Solomon, B., Loong, H. H., Park, K., Pérol, M., Arriola, E., Novello, S., Han, B., Zhou, J., Ardizzoni, A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2309457 · Cited by 233
Field, J. K., Vulkan, D., Davies, M. P. A., Baldwin, D. R., Brain, K. E., Devaraj, A., Eisen, T., Gosney, J., Green, B. A., Holemans, J. A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100179 · Cited by 230
Self-citationMino-Kenudson, M., Schalper, K., Cooper, W., Dacic, S., Hirsch, F. R., Jain, D., Lopez-Rios, F., Tsao, M. S., Yatabe, Y., Beasley, M. B., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.109 · Cited by 226
Self-citationGarassino, M. C., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., Domine, M., Hochmair, M. J., Powell, S., Cheng, S. Y.-S., Bischoff, H. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30801-0 · Cited by 215
Self-citationComutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC
Negrao, M. V., Araujo, H. A., Lamberti, G., Cooper, A. J., Akhave, N. S., Zhou, T., Delasos, L., Hicks, J. K., Aldea, M., Minuti, G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1420 · Cited by 203
Self-citationDeep Learning Reconstruction Shows Better Lung Nodule Detection for Ultra–Low-Dose Chest CT
Jiang, B., Li, N., Shi, X., Zhang, S., Li, J., de Bock, G. H., Vliegenthart, R., & Xie, X. (2022) · Radiology · doi:10.1148/radiol.210551 · Cited by 202
Mountzios, G., Remon, J., Hendriks, L. E. L., García-Campelo, R., Rolfo, C., Van Schil, P., Forde, P. M., Besse, B., Subbiah, V., Reck, M., et al. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00794-7 · Cited by 199
Self-citationJett, J. R., Peek, L. J., Fredericks, L., Jewell, W., Pingleton, W. W., & Robertson, J. F. R. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.008 · Cited by 195
De Ruysscher, D., Botterweck, A., Dirx, M., Pijls-Johannesma, M., Wanders, R., Hochstenbag, M., Dingemans, A.-M. C., Bootsma, G., Geraedts, W., Simons, J., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn559 · Cited by 186
Reck, M., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100273 · Cited by 186
Self-citationKatki, H. A., Kovalchik, S. A., Petito, L. C., Cheung, L. C., Jacobs, E., Jemal, A., Berg, C. D., & Chaturvedi, A. K. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2701 · Cited by 184
Chang, G.-C., Chiu, C.-H., Yu, C.-J., Chang, Y.-C., Chang, Y.-H., Hsu, K.-H., Wu, Y.-C., Chen, C.-Y., Hsu, H.-H., Wu, M.-T., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00338-7 · Cited by 177
Vaping and lung cancer – A review of current data and recommendations
Bracken-Clarke, D. M., Kapoor, D., Baird, A., Buchanan, P., Gately, K. A., Cuffe, S. D., & Finn, S. P. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.030 · Cited by 174
Paz-Ares, L. G., Juan, Ó., Mountzios, G., Felip, E., Reinmuth, N., de Marinis, F., Girard, N., Patel, V. M., Takahama, T., Owen, S. P., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00733 · Cited by 174
Self-citationMulti-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma
Hu, X., Fujimoto, J., Ying, L., Fukuoka, J., Ashizawa, K., Sun, W., Reuben, A., Chow, C.-W., McGranahan, N., Chen, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10877-8 · Cited by 173
Self-citationLung Cancer and Lung Stem Cells: Strange Bedfellows?
Giangreco, A., Groot, K. R., & Janes, S. M. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200607-984pp · Cited by 169
Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins
Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida, F., Sun, N., Bantis, L. E., Muller, D. C., Li, P., Taguchi, A., Dhillon, D., Kundnani, D. L., Patel, N. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2078 · Cited by 169
Lee, S. M., Schulz, C., Prabhash, K., Kowalski, D., Szczesna, A., Han, B., Rittmeyer, A., Talbot, T., Vicente, D., Califano, R., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00774-2 · Cited by 167
Self-citationCarrot‐Zhang, J., Soca‐Chafre, G., Patterson, N. J., Thorner, A. R., Nag, A., Watson, J., Genovese, G., Rodríguez, J. K., Gelbard, M. K., Corrales, L., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1165 · Cited by 164
Spicer, J. D., Cascone, T., Wynes, M. W., Ahn, M.-J., Dacic, S., Felip, E., Forde, P. M., Higgins, K. A., Kris, M. G., Mitsudomi, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.06.010 · Cited by 161
Dejima, H., Hu, X. Y., Chen, R., Zhang, J., Fujimoto, J., Parra, E. R., Haymaker, C., Hubert, S. M., Duose, D. Y., Solis, L. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22890-x · Cited by 156
Self-citationPeters, S., Felip, E., Dafni, U. G., Tufman, A., Gückenberger, M., Álvarez, R., Nadal, E., Becker‐Commissaris, A., Vees, H., Pless, M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.129 · Cited by 155
Antibody-drug conjugates in lung cancer: dawn of a new era?
Coleman, N., Yap, T. A., Heymach, J. V., Meric‐Bernstam, F., & Le, X. (2023) · npj Precision Oncology · doi:10.1038/s41698-022-00338-9 · Cited by 155
Self-citationSullivan, F., Mair, F. S., Anderson, W., Armory, P., Briggs, A. H., Chew, C., Dorward, A., Haughney, J., Hogarth, F., Kendrick, D., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00670-2020 · Cited by 154
Marquette, C., Boutros, J., Benzaquen, J., Ferreira, M., Pastré, J., Pison, C. M., Padovani, B., Bettayeb, F., Fallet, V., Guibert, N. M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30081-3 · Cited by 152
Garassino, M. C., Mazières, J., Reck, M., CHOUAID, C., Bischoff, H. G., Reinmuth, N., Cove-Smith, L., Mansy, T., Cortinovis, D. L., Migliorino, M. R., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.07.1148 · Cited by 152
Self-citationEuropean cancer mortality predictions for the year 2023 with focus on lung cancer
Malvezzi, M., Santucci, C., Boffetta, P., Collatuzzo, G., Levi, F., Vecchia, C. L., & Negri, E. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.010 · Cited by 149
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers
Devarakonda, S., Li, Y., Rodrigues, F. M., Sankararaman, S., Kadara, H. N., Goparaju, C., Lanc, I., Pepin, K., Waqar, S. N., Morgensztern, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01691 · Cited by 143
Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening
Yang, W., Qian, F., Teng, J., Wang, H., Manegold, C., Pilz, L. R., Voigt, W., Zhang, Y., Ye, J., Chen, Q., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.003 · Cited by 141
European cancer mortality predictions for the year 2024 with focus on colorectal cancer
Santucci, C., Mignozzi, S., Malvezzi, M., Boffetta, P., Collatuzzo, G., Levi, F., Vecchia, C. L., & Negri, E. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.12.003 · Cited by 140
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
Passaro, A., Janne, P. A., & Peters, S. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00013 · Cited by 135
The effect of MPOWER scores on cigarette smoking prevalence and consumption
Ngô, Á. N., Cheng, K., Chaloupka, F. J., & Shang, C. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2017.05.006 · Cited by 132
Kerpel-Fronius, A., Tammemägi, M. C., Cavic, M. R., Henschke, C. I., Jiang, L., Kazerooni, E. A., Lee, C., Ventura, L., Yang, D., Lam, S. C., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.07.031 · Cited by 131
Lim, E. K. S., Harris, R. A., McKeon, H. E., Batchelor, T. J. P., Dunning, J., Shackcloth, M. J., Anikin, V., Naidu, B. V., Belcher, E., Loubani, M., et al. (2022) · Health Technology Assessment · doi:10.3310/thbq1793 · Cited by 128
Cho, B. C., Lee, J. S., Wu, Y.-L. L. C., Çiçin, İ., Cobo, M., Ahn, M., Cuppens, K., Veillon, R., Nadal, E., Dias, J. M., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.018 · Cited by 126
Self-citationChang, J. C., Alex, D., Bott, M. J., Tan, K. S., Seshan, V., Golden, A., Sauter, J. L., Buonocore, D. J., Vanderbilt, C., Gupta, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1700 · Cited by 120
Pulmonary preneoplasia – sequential molecular carcinogenetic events
Lantuéjoul, S., Salameire, D., Salon, C., & Brambilla, E. M. (2009) · Histopathology · doi:10.1111/j.1365-2559.2008.03182.x · Cited by 119
Risk Stratification for Second Primary Lung Cancer
Han, S. S., Rivera, G. A., Tammemägi, M. C., Plevritis, S. K., Gomez, S. L., Cheng, I. C., & Wakelee, H. A. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.4203 · Cited by 119
Felip, E., Shaw, A. T., Bearz, A., Camidge, D. R., Solomon, B., Bauman, J. R., Bauer, T. M., Peters, S., Toffalorio, F., Abbattista, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.012 · Cited by 119
Tumor Evolutionary Principles: How Intratumor Heterogeneity Influences Cancer Treatment and Outcome
Venkatesan, S., & Swanton, C. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_158930 · Cited by 119
Tsujino, K., Kurata, T., Yamamoto, S., Kawaguchi, T., Kubo, A., Isa, S., Hasegawa, Y., Ou, S. I., Takada, M., & Ando, M. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182988348 · Cited by 115
Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment
Fahrmann, J. F., Marsh, T. L., Irajizad, E., Patel, N. J., Murage, E. N., Vykoukal, J. V., Dennison, J. B., Do, K.-A., Ostrin, E. J., Spitz, M. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01460 · Cited by 114
Borghaei, H., de Marinis, F., Dumoulin, D. W., Reynolds, C. H., Theelen, W. S. M. E., Percent, I. J., Calderón, V. G., Johnson, M. L., Madroszyk, A., Garon, E. B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.004 · Cited by 113
Self-citationIyengar, P., Hu, C., Gomez, D. R., Timmerman, R. D., Simone, C. B., Robinson, C. G., Gerber, D. E., Waqar, S. N., Donington, J. S., Swisher, S. G., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.16_suppl.8506 · Cited by 110
Steuer, C. E., Behera, M., Ernani, V., Higgins, K. A., Saba, N. F., Shin, D. M., Pakkala, S., Pillai, R. N., Owonikoko, T. K., Curran, W. J., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4280 · Cited by 109
Cascone, T., Awad, M. M., Spicer, J. D., He, J., Lü, S., Sepesi, B., Tanaka, F., Taube, J. M., Cornelissen, R., Havel, L., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.050 · Cited by 109
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas
Hu, X., Estecio, M. R., Chen, R., Reuben, A., Wang, L., Fujimoto, J., Carrot‐Zhang, J., McGranahan, N., Ying, L., Fukuoka, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20907-z · Cited by 106
Self-citationCortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 105
Self-citationImmune Surveillance in Clinical Regression of Preinvasive Squamous Cell Lung Cancer
Pennycuick, A., TEIXEIRA, V. H., AbdulJabbar, K., Raza, S. E. A., Lund, T., Akarca, A. U., Rosenthal, R., Kalinke, L., Chandrasekharan, D. P., Pipinikas, C., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1366 · Cited by 101
The Role of DNA Methylation in the Development and Progression of Lung Adenocarcinoma
Kerr, K. M., Galler, J. S., Hagen, J. A., Laird, P. W., & Laird‐Offringa, I. A. (2007) · Disease Markers · doi:10.1155/2007/985474 · Cited by 99
Self-citationKotton, D. N., & Fine, A. (2007) · Cell and Tissue Research · doi:10.1007/s00441-007-0479-2 · Cited by 98
MacRosty, C. R., & Rivera, M. P. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.10.005 · Cited by 98
Utility of polygenic risk scores in UK cancer screening: a modelling analysis
Huntley, C., Torr, B., Sud, A., Rowlands, C. F., Way, R., Snape, K. M. G., Hanson, H., Swanton, C., Broggio, J., Lucassen, A., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00156-0 · Cited by 97
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
Blaquier, J. B., Ortiz‐Cuaran, S., Ricciuti, B., Mezquita, L., Cardona, A. F., & Recondo, G. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1912 · Cited by 96
Lü, S., Wu, L., Zhang, W., Zhang, P., Wang, W., Fang, W., Xing, W., Chen, Q., Mei, J., Yang, L. T., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.36_suppl.425126 · Cited by 94
Mazières, J., Kowalski, D. M., Luft, A. V., Vicente, D., Tafreshi, A., Gümüş, M., Лактионов, К. К., Hermes, B., Çiçin, İ., Rodríguez‐Cid, J. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01348 · Cited by 92
Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer
Rivera‐Concepción, J., Uprety, D., & Adjei, A. A. (2022) · Cancer Research and Treatment · doi:10.4143/crt.2022.078 · Cited by 92
Lung cancer and lung stem cells - Strange bedfellows?
Giangreco, A., Groot, K., & Janes, S. (2007) · UCL Discovery (University College London) · Cited by 88
Besse, B., Felip, E., Campelo, R. G., Cobo, M., Mascaux, C., Madroszyk, A., Cappuzzo, F., Hilgers, W., Romano, G. D., Denis, F., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.006 · Cited by 86
Research works printed but not linked: 28
- World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Use 2000–2025, fourth edition (WHO, 2021).
- Akhtar-Danseh, G. G., Akhtar-Danesh, N. & Finley, C. Uptake and survival effects of minimally invasive surgery for lung cancer: a population-based study. Eur. J. Surg. Oncol. 47, 1791–1796 (2021). · doi:10.1016/j.ejso.2021.01.002
- WHO Classification of Tumours Editorial Board. Thoracic Tumours, WHO Classification of Tumours 5th edn, Vol. 5 (WHO, 2021).
- Kerr, K. M. in Molecular Pathology of Lung Cancer (eds. Cagle, P. T. et al.) 35–52 (Springer, 2012). A key overview of the molecular classification of lung cancer. · doi:10.1007/978-1-4614-3197-8_5
- Minna, J. D., Fong, K., Zöchbauer-Müller, S. & Gazdar, A. F. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J. 8, S41–S46 (2002).
- Amin, M. et al. AJCC Cancer Staging Manual 8th edn (Springer, 2017).
- Hendriks, L. E. et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 339–357 (2023). European Society for Medical Oncology recommendations on the management of oncogene-addicted NSCLC. · DOI · Paper page
- Poon, C., Wilsdon, T., Sarwar, I., Roediger, A. & Yuan, M. Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption. Front. Public Health 11, 1264342 (2023). · doi:10.3389/fpubh.2023.1264342
- Hanash, S. M., Ostrin, E. J. & Fahrmann, J. F. Blood based biomarkers beyond genomics for lung cancer screening. Transl. Lung Cancer Res. 7, 327–335 (2018). · doi:10.21037/tlcr.2018.05.13
- Heiden, B. T. et al. Association between surgical quality metric adherence and overall survival among US veterans with early-stage non-small cell lung cancer. JAMA Surg. 158, 293–301 (2023). · doi:10.1001/jamasurg.2022.6826
- Whitson, B. A., D’Cunha, J. & Maddaus, M. A. Minimally invasive cancer surgery improves patient survival rates through less perioperative immunosuppression. Med. Hypotheses 68, 1328–1332 (2007). · doi:10.1016/j.mehy.2006.09.063
- Veronesi, G. et al. Robotic resection of Stage III lung cancer: an international retrospective study. Eur. J. Cardiothorac. Surg. 54, 912–919 (2018). · doi:10.1093/ejcts/ezy166
- Savonitto, E., Yasufuku, K. & Wallace, A. M. Robotic segmentectomy for early-stage lung cancer. Front. Surg. 10, 1090080 (2023). · doi:10.3389/fsurg.2023.1090080
- Veronesi, G. et al. Perioperative outcome of robotic approach versus manual videothoracoscopic major resection in patients affected by early lung cancer: results of a randomized multicentric study (ROMAN study). Front. Oncol. 11, 726408 (2021). · doi:10.3389/fonc.2021.726408
- Patel, Y. S. et al. RAVAL trial: protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer. PLoS ONE 17, e0261767 (2022). · doi:10.1371/journal.pone.0261767
- Houda, I. et al. OA06.03. An international EORTC survey on resectability of stage III non-small cell lung cancer. J. Thorac. Oncol. 18, S55–S56 (2023). · doi:10.1016/j.jtho.2023.09.044
- Dingemans, A. M. et al. OA06.05. Consensual definition of stage III NSCLC resectability: EORTC-lung cancer group initiative with other scientific societies. J. Thorac. Oncol. 18, S57–S58 (2023). · doi:10.1016/j.jtho.2023.09.046
- Perez, C. A. et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45, 2744–2753 (1980). · doi:10.1002/1097-0142(19800601)45:11<2744::aid-cncr2820451108>3.0.co;2-u
- Filippi, A. R. R. et al. LBA62. Durvalumab after radiotherapy (RT) in patients with unresectable stage III NSCLC ineligible for chemotherapy (CT): primary results from the DUART study. Ann. Oncol. 34, S1302 (2023). · doi:10.1016/j.annonc.2023.10.058
- Ko, R. et al. 1292MO. A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A. Ann. Oncol. 34, S745–S746 (2023). · doi:10.1016/j.annonc.2023.09.770
- Hendriks, L. E. et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 358–376 (2023). · DOI · Paper page
- Genentech. Genentech reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer. gene.com https://www.gene.com/media/press-releases/14951/2022-05-10/genentech-reports-interim-results-for-ph (2022).
- Neal, J. et al. 60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. J. Thorac. Oncol. 18, S39–S40 (2023). · doi:10.1016/s1556-0864(23)00260-5
- Paz-Ares, L. et al. 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3 L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results. Ann. Oncol. 32, S953–S954 (2021). · doi:10.1016/j.annonc.2021.08.1799
- Ahn, M. J. et al. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Ann. Oncol. 34, S1305–S1306 (2023). · doi:10.1016/j.annonc.2023.10.061
- Sanofi announces end of program evaluating tusamitamab ravtansine after a 2 L NSCLC phase 3 trial did not meet a primary endpoint. Sanofi https://www.sanofi.com/en/media-room/press-releases/2023/2023-12-21-06-30-00-2799759 (2023).
- Camidge, D. R. et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: primary analysis of the LUMINOSITY trial. J. Clin. Oncol. 42, 103–103 (2024). · doi:10.1200/jco.2024.42.16_suppl.103
- Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst. Rev. 5, CD007309 (2010). A Cochrane Review providing confirmation of the efficacy of chemotherapy in advanced NSCLC.
Cited by
Zheng, Q., Liu, Y., Li, T., Zhang, X., Geng, Y., Chen, Z., Zhou, J., Fan, W., Wang, Y., Zhang, L., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1871582
Metadata
- Authors
- Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M.
- Venue
- Nature Reviews Disease Primers
- Published
- 2024-09-26
- Volume
- 10
- Issue
- 1
- Pages
- 71-71
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4402886999
- Cited by
- 568
- References
- 257
- FWCI
- 68.13
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-01-07)
- Open access
- green
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.